, NO (38.43 ± 3.32 umol/L) and NOS (42.65 ± 3.32 U/mL) were increased. and reduced MDA (9.13 ± 2.12 nmol/mL) and NO (22.37 ± 3.16 umol/L) levels (p < 0.05). High-dose DNE also led to significant decreases in CK (0.53 ± 0.35 U/mL) and NOS (24.27 ± 3.55U/mL) 
INTRODUCTION
Chronic heart failure (CHF) is a consequence of cardiac disorder [1] . The incidence of heart failure (HF) in developed countries for people over 65 years old is about 1 % [2] . It has been shown that the morbidity from HF in ten provinces of China has reached 0.9 % [3] . However, it must be noted that the current prognosis of CHF is far from satisfactory, and therapeutic regimens are limited. To some extent, the situation is much worse for HF than cancer [4] . Furthermore, hospitalization burden and healthcare expenditures make HF a global health issue.
The frequently adopted treatments for HF include angiotensin-converting enzyme (ACE) inhibitors, β-adrenoceptor blockers, and digitalis [5] [6] [7] . Although the guidelines on CHF therapy have been updated by American Heart Association (AHA) and European Society of Cardiology (ESC) [2] , HF remains a major cause death [8] . Thus there is need to explore new therapeutic regimens for HF.
The use of Traditional Chinese Medicine (TCM) for treatment of complex, multi-factorial diseases is gaining acceptance. It has been recognized that TCM effectively treats symptoms, reduce side effects and reverse resistance via targeting multiple pathways. TCMs such as Shengmai [9] , Sini decoction [10] , Shuanglong formula [11] , and Huangqi injection have been reported to exhibit potential pharmacological activities against cardiovascular diseases [12] . Draba nemorosa stimulates blood circulation, thus eliminating blood stasis. It also contributes to replenishment of blood, reduces swelling and relieves pain [13, 14] . So far, there are no reports in the literature on the use of Draba nemorosa for treating cardiovascular diseases. This study was aimed at investigating the effect of DNE on CHF in a rat model. 
EXPERIMENTAL Materials

Modeling and treatment
The experimental groups consisted of control group, adriamycin-treated CHF group, captopril group (0.1 g/kg), as well as high, middle and lowdose (5.2, 2.6 and 1.3 g/kg, DNE groups, respectively, n = 10). Rats in the control group were administered an equivalent volume of saline in place of adriamycin hydrochloride (2 mg/kg). Adriamycin rat model established via administration of the drug, once a week for 6 weeks.
At the 6th week, 2 rats were chosen and checked for heart failure. The adriamycin administration was extended for a further 4 weeks for rats that had not successfully developed heart failure (untreated rats). Drug administration began from the 7th week of the experiment and lasted for 4 weeks. Except for the administration of saline to the control and adriamycin-induced CHF animals, DNE group received 1.3, 2.6 or 5.2 g/kg DNE once a day intra-gastrically, with 100 mg/kg captopril administrated to the captopril group only.
Determination of cardiac function and hemodynamics
Twenty-four h to the end of the experiment, the rats were anesthetized with 20% urethane solution (6 mL/kg). Then the animals were fixed in a spinal position. Ventricular cannula was used to separate the right common carotid artery using 1.0 % heparin. Parameters concerning cardiac function were determined, and observation of pressure oscilloscope was performed. The advance was stopped when transformation of the wave shape was observed and the pulse pressure significantly was uplifted. The parameters recorded were LVSP, LVEDP, +dp/dt max and -dp/dt max . Mean values of the hemodynamic indices were obtained for calculations in 5 sections. Blood samples were thereafter collected from the abdominal aorta. Half of the blood samples were in sodium EDTA bottles, while the other half were without anticoagulant. All the samples were stored at -20 o C before analysis.
Measurement of heart index
Heart index (HI) was determined after cardiac function and hemodynamics measurements. The weight of the whole heart was measured, and the heart weight index was calculated as the ratio of whole heart weight (mg) to body weight (g).
Determination of serum biochemical indices
Serum CK, SOD, MDA, NO and NOS were determined using ELISA kits (Shenzhen Xin Bo Sheng Biological Technology Co., Ltd., Shenzhen, China) according to manufacturer's
Statistical analysis
Data are expressed as mean ± standard error of mean (SEM). Statistical Package SPSS 16.0 (SPSS Inc, Illinois, Chicago, USA) was applied for data analysis using one-way analysis of variance (ANOVA) and Dunnett's t-test. Statistical significance was set at p < 0.05.
RESULTS
Effect of DNE on heart index
There was a significant increase in HI in the model group when compared with the normal group (p < 0.05), which is an indication that myocardial hypertrophy was successfully established in the model group (Table 1) . On the contrary, there was no significant variation in HI in the captopril and DNE groups. 
Effect of DNE on hemodynamic parameters
There were sharp decreases in SBP, DBP, MAP, LVSP, ± dp/dtmax and HR in the adriamycintreated CHF group, when compared with control (p < 0.05). Significant increases in LVEDP (p < 0.01) were observed in the model group relative to the control group, but DNE (high dose) was able to bring about a significant reduction in this parameter. Moreover, DNE led to significant improvement in vasomotoricity and left ventricular function in adriamycin-treated CHF rats (p < 0.05), while captopril exhibited very little effect (Tables 2 and 3 ).
Effect of DNE on serum biochemical indices
There were significant increases (p < 0.01) in blood levels of CK, NOS, MDA, and NO levels, and sharp decreases (p < 0.01) in activity of SOD in blood of rats in the CHF group, when compared with control. However, captopril administration brought about significant reductions in CHF-induced increases in blood levels of CK, NOS, MDA, and NO (p < 0.01), while DNE had no significant effect on SOD activity; Table 4 ).
DISCUSSION
In this study, cardiac function was assessed by various hemodynamic parameters. The results obtained suggest that diastolic function and contraction could be improved by DNE.
The left ventricular function was appreciably improved without affecting heart rate. It appeared that DNE exhibited higher pharmacological activity than captopril. Heart failure can be induced by oxidative stress [16] , since reactive oxygen species and nitric oxide are involved in the process. Free radicals induce lipid peroxidation which damages cell membranes and accelerates cell apoptosis. Physiological antioxidants neutralize these free radicals, and NO is a physiological vasodilator. However, high levels of NO can lead to free radical formation and result in serious neurotoxicity, thus damaging the tissues. The synthesis of NO requires NOS [17] . In this study, DNE significantly reversed the CHF-induced increases in MDA and NO levels, and also decreased CK and NOS activities. Thus DNE reduced the oxidative stress state brought about by CHF. However, DNE had no significant effect on the activity of SOD, suggesting the effect of DNE was not mediated via SOD.
CONCLUSION
The findings of this study has demonstrated that DNE appreciably ameliorates chronic congestive heart failure, most probably by mitigation of oxidative stress, and the recovery of left ventricular function. Thus, DNE may be a potential source of new drug(s) for treating chronic heart failure in future.
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